Neuronetics, Inc. (STIM): Entry into a Material Definitive Agreement
Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Neuronetics Announces Proposed Public Offering of Common Stock MALVERN, Pa., November 10, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar ® TMS technology an
- Instrument
- common stock
- Use of proceeds
- prepayment of a portion of the outstanding term loans under the Perceptive Facility
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The capital raise could strengthen the balance sheet but may temporarily depress the share price.
Market read
Primary disclosure of a material equity offering; relevant for traders with exposure to STIM.
What to watch
The amendment to the credit facility may improve liquidity, reducing near‑term financial risk.
Background
Neuronetics is a provider of TMS therapy and operates a network of psychiatry clinics.
Ticker impact
Neuronetics filed an 8‑K announcing an underwritten public offering of its common stock, the first disclosure of this capital raise.
downward pressure as the market prices in dilution risk
Primary disclosure of a material equity raise typically leads to short‑term share price weakness.
Market effects
May affect other mental‑health and med‑tech firms as investors reassess financing needs.
Limited to U.S. markets where the stock trades.
Low, as the offering is company‑specific.
Counterpoint
If the proceeds fund high‑margin growth initiatives, the dilution could be offset by future earnings upside.
Key entities
- companyNeuronetics, Inc.
Issuer of the public offering.
- underwriterWilliam Blair
Lead bookrunning manager for the offering.

